

Asia Pacific Immunodiagnosics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)

Market Report | 2023-10-26 | 225 pages | The Insight Partners

AVAILABLE LICENSES:

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

Report description:

The Asia Pacific immunodiagnosics market is expected to grow from US\$ 2,409.90 million in 2023 to US\$ 4,252.35 million by 2030. It is estimated to grow at a CAGR of 8.5% from 2023 to 2030.

Technological Advancements in Immunodiagnosics Drive Asia Pacific Industrial Robotics Market

The current trend in immunodiagnosics is microfluidics and magnetic beads with potential commercialization. These sensitive, specific, and time-saving methodologies are essential in understanding and diagnosing health conditions, such as infectious diseases, metabolic disorders, and cardiac problems.

The increasing applications of immunodiagnosics solutions encouraged the development of targeted treatments and therapies for precision health. The prominent market players also promote assay technologies, microfluidics, and magnetic beads. For immunoassays, magnetic particles, such as Sera-Mag beads, offer a convenient alternative to plate-based ELISAs, as both rely on the same assay principle. Merck KGaA launched the Magna Chip Protein A magnetic beads. This recombinant Protein A is

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

covalently bound to magnetic beads for chromatin immunoprecipitations (Chip assays), providing users with a faster, reproducible, and more efficient reagent for collecting immunocomplexes than agarose beads.

In microfluidics, some immunodiagnosics target single biomarkers. However, a recent trend shows the detection of multiple analytes according to the complexity and the need to make early reliable diagnoses.

In September 2023, Siemens Healthineers released its new CE-marked SARS-CoV-2/FluA/FluB/HRSV assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test. The new FTD SARS-CoV-2/FluA/FluB/HRSV assay enables comprehensive and semi-automated molecular testing for seasonal respiratory pathogens. The combination PCR test detects and differentiates clinically relevant viruses such as SARS-CoV-2, Influenza A, Influenza B, and HRSV A/B.

Asia Pacific Immunodiagnosics Market Overview

According to Statista, a large chunk of the Chinese population was suffering from chronic diseases in 2020. Almost 80% of deaths among people aged 60 years in the country are caused due to chronic NCDs, of which the most severe are ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and Type II diabetes. According to China Blueprint, immunological diagnosis has exceeded biochemical diagnosis (accounting for 27%), and the in vitro diagnostics (IVD) market has gone mainstream in China. However, compared to developed countries, there is still room for alternative biochemical diagnosis to expand in China's immunodiagnosics market, as the average ratio of biochemical to immunization diagnosis is about 1:2, according to statistical data from several agencies. As technological innovation advances with the growing need for high-end testing, diagnostics is expected to consolidate its mainstream status.

Furthermore, collaborations between organizations are increasing for developing and producing assays. For instance, in December 2023, Ortho Clinical Diagnostics Trading and Shanghai Medconn Biotechnology signed an agreement as part of a joint venture to develop and manufacture assays for the VITROS immunodiagnosics platform in China. The expertise of Ortho Clinical Diagnostics Trading in developing and designing in vitro diagnostics (IVD) technologies for POC settings, clinical labs, and transfusion medicine will propel the growth of the Asia Pacific immunodiagnosics market in the coming years.

Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

Asia Pacific Immunodiagnosics Market Segmentation

The Asia Pacific immunodiagnosics market is segmented into product, clinical indication, end user, and country.

Based on product, the Asia Pacific immunodiagnosics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered a largest share in the Asia Pacific immunodiagnosics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the Asia Pacific immunodiagnosics market is segmented into infectious diseases, hepatitis HIV, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered a largest share in the Asia Pacific immunodiagnosics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the Asia Pacific immunodiagnosics market is segmented into hospitals, clinics, diagnostic laboratories,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

academic & research institutes, and others. In 2023, the hospitals segment registered a largest share in the Asia Pacific immunodiagnostics market.

Based on country, the Asia Pacific immunodiagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2023, China registered a largest share in the Asia Pacific immunodiagnostics market.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific immunodiagnostics market.

Table of Contents:

TABLE OF CONTENTS

- 1. Introduction
 - 1.1 Scope of the Study
 - 1.2 The Insight Partners Research Report Guidance
 - 1.3 Market Segmentation
 - 1.3.1 Asia Pacific Immunodiagnostics Market - by Product
 - 1.3.2 Asia Pacific Immunodiagnostics Market - by Clinical Indication
 - 1.3.3 Asia Pacific Immunodiagnostics Market - by End User
 - 1.3.4 Asia Pacific Immunodiagnostics Market - by Country
- 2. Asia Pacific Immunodiagnostics Market - Key Takeaways
- 3. Research Methodology
 - 3.1 Coverage
 - 3.2 Secondary Research
 - 3.3 Primary Research
- 4. Asia Pacific Immunodiagnostics Market - Market Landscape
 - 4.1 Overview
 - 4.2 Asia Pacific PEST Analysis
 - 4.3 Expert's Opinion
- 5. Asia Pacific Immunodiagnostics Market - Key Market Dynamics
 - 5.1 Market Drivers
 - 5.1.1 Increasing Prevalence of Infectious Diseases
 - 5.1.2 Growing Use of Point-of-Care Immunodiagnostics
 - 5.2 Market Restraints
 - 5.2.1 Inadequate Reimbursement Scenario
 - 5.3 Market Opportunities
 - 5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
 - 5.4 Future Trends
 - 5.4.1 Technological Advancements in Immunodiagnostics
 - 5.5 Impact Analysis
- 6. Immunodiagnostics Market - Asia Pacific Analysis
 - 6.1 Asia Pacific Immunodiagnostics Market Revenue Forecast and Analysis
- 7. Asia Pacific Immunodiagnostics Market Analysis - by Product
 - 7.1 Overview
 - 7.2 Asia Pacific Immunodiagnostics Market, By Product, 2022 & 2030 (%)
 - 7.3 Enzyme-linked Immunosorbent Assays (ELISA)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.3.1 Overview	
7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
7.4 Chemiluminescence Immunoassays (CLIA)	
7.4.1 Overview	
7.4.2 Chemiluminescence Immunoassays (CLIA): Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
7.4.3 Vitamin D Assay	
7.4.3.1 Overview	
7.4.3.2 Vitamin D Assay: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
7.4.4 HIV Detection	
7.4.4.1 Overview	
7.4.4.2 HIV Detection: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
7.4.5 HIV Ag/Ab Combo assay	
7.4.5.1 Overview	
7.4.5.2 HIV Ag/Ab Combo Assay: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
7.4.6 Other Tests	
7.4.6.1 Overview	
7.4.6.2 Other Tests: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
7.5 Radioimmunoassays (RIA)	
7.5.1 Overview	
7.5.2 Radioimmunoassays (RIA): Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
7.6 Others	
7.6.1 Overview	
7.6.2 Others: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8. Asia Pacific Immunodiagnosics Market Analysis - Clinical Indication	
8.1 Overview	
8.2 Asia Pacific Immunodiagnosics Market Share by Clinical Indication - 2022 & 2030 (%)	
8.3 Infectious Diseases:	
8.3.1 Overview	
8.3.2 Infectious Diseases: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.3.2.1 COVID-19	
8.3.2.1.1 Overview	
8.3.2.1.2 COVID-19: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.3.2.2 Tuberculosis	
8.3.2.2.1 Overview	
8.3.2.2.2 Tuberculosis: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.3.2.3 Lyme	
8.3.2.3.1 Overview	
8.3.2.3.2 Lyme: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.3.2.4 Infection Management	
8.3.2.4.1 Overview	
8.3.2.4.2 Infection Management: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.3.2.5 Zika	
8.3.2.5.1 Overview	
8.3.2.5.2 Zika: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.3.2.6 Treponema	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.3.2.6.1 Overview	
8.3.2.6.2 Treponema: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.3.2.7 TORCH	
8.3.2.7.1 Overview	
8.3.2.7.2 TORCH: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.3.2.8 Measles and Mumps	
8.3.2.8.1 Overview	
8.3.2.8.2 Measles and Mumps: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.3.2.9 VZV	
8.3.2.9.1 Overview	
8.3.2.9.2 VZV: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.3.2.10 EBV	
8.3.2.10.1 Overview	
8.3.2.10.2 EBV: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.4 Hepatitis+HIV:	
8.4.1 Overview	
8.4.2 Hepatitis+HIV: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.5 Gastrointestinal	
8.5.1 Overview	
8.5.2 Gastrointestinal: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.6 Metabolic Disorders	
8.6.1 Overview	
8.6.2 Metabolics: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.7 Endocrinology	
8.7.1 Overview	
8.7.2 Endocrinology: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.7.3 Hypertension	
8.7.3.1 Overview	
8.7.3.2 Hypertension: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.7.4 Growth	
8.7.4.1 Overview	
8.7.4.2 Growth: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.7.5 Diabetes	
8.7.5.1 Overview	
8.7.5.2 Diabetes: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.7.6 Thyroid	
8.7.6.1 Overview	
8.7.6.2 Thyroid: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.7.7 Reproductive Endocrinology	
8.7.7.1 Overview	
8.7.7.2 Reproductive Endocrinology: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
8.8 Others	
8.8.1 Overview	
8.8.2 Others: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
9. Asia Pacific Immunodiagnosics Market Analysis - End User	
9.1 Overview	
9.2 Asia Pacific Immunodiagnosics Market Share by End User - 2022 & 2030 (%)	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.3 Hospitals	
9.3.1 Overview	
9.3.2 Hospitals: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
9.4 Clinics	
9.4.1 Overview	
9.4.2 Clinics: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
9.5 Diagnostic Laboratories	
9.5.1 Overview	
9.5.2 Diagnostic Laboratories: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
9.6 Academic and Research Institutes	
9.6.1 Overview	
9.6.2 Academic and Research Institutes: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
9.7 Others	
9.7.1 Overview	
9.7.2 Others: Asia Pacific Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)	
10. Asia Pacific Immunodiagnosics Market - Revenue and Forecast to 2030 - Country Analysis	
10.1 Overview	
10.1.1.1 China: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.1.1 Overview	
10.1.1.1.2 China: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.1.3 China: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)	
10.1.1.1.3.1 China: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.1.4 China: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.1.4.1 China: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.1.4.2 China: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.1.5 China: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)	
10.1.1.2 Japan: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.2.1 Overview	
10.1.1.2.2 Japan: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.2.3 Japan: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)	
10.1.1.2.3.1 Japan: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.2.4 Japan: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.2.4.1 Japan: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.2.4.2 Japan: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.2.5 Japan: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)	
10.1.1.3 India: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.3.1 Overview	
10.1.1.3.2 India: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.3.3 India: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)	
10.1.1.3.3.1 India: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.3.4 India: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.3.4.1 India: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.3.4.2 India: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)	
10.1.1.3.5 India: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1.1.4 Australia: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.4.1 Overview
 - 10.1.1.4.2 Australia: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.4.3 Australia: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
 - 10.1.1.4.3.1 Australia: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.4.4 Australia: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.4.4.1 Australia: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.4.4.2 Australia: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.4.5 Australia: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
 - 10.1.1.5 South Korea: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.5.1 Overview
 - 10.1.1.5.2 South Korea: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.5.3 South Korea: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
 - 10.1.1.5.3.1 South Korea: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.5.4 South Korea: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.5.4.1 South Korea: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.5.4.2 South Korea: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.5.5 South Korea: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
 - 10.1.1.6 Rest of Asia Pacific: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.6.1 Overview
 - 10.1.1.6.2 Rest of Asia Pacific: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.6.3 Rest of Asia Pacific: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
 - 10.1.1.6.3.1 Rest of Asia Pacific: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.6.4 Rest of Asia Pacific: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.6.4.1 Rest of Asia Pacific: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.6.4.2 Rest of Asia Pacific: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
 - 10.1.1.6.5 Rest of Asia Pacific: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
 - 11. Asia Pacific Immunodiagnosics Market -Industry Landscape
 - 11.1 Overview
 - 11.2 Inorganic Growth Strategies
 - 11.2.1 Overview
 - 11.3 Organic Growth Strategies
 - 11.3.1 Overview
 - 12. Company Profiles
 - 12.1 Abbott Laboratories
 - 12.1.1 Key Facts
 - 12.1.2 Business Description
 - 12.1.3 Products and Services
 - 12.1.4 Financial Overview
 - 12.1.5 SWOT Analysis
 - 12.1.6 Key Developments
 - 12.2 F. Hoffmann-La Roche Ltd
 - 12.2.1 Key Facts
 - 12.2.2 Business Description

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 DiaSorin SpA
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Danaher Corp
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Thermo Fisher Scientific Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 PerkinElmer Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 bioMérieux SA
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 Svar Life Science AB

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 12.10 Siemens Healthcare GmbH
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
- 13. Appendix
- 13.1 About The Insight Partners
- 13.2 Glossary of Terms

Asia Pacific Immunodiagnostics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)

Market Report | 2023-10-26 | 225 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-05"/>
		Signature	<input type="text"/>